Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Anti-ROR1 Antibody (Zilovertamab): Mechanism, Evidence, and

    2026-04-14

    Anti-ROR1 Antibody (Zilovertamab): Mechanism, Evidence, and Use

    Executive Summary: Anti-ROR1 Antibody (Zilovertamab, F1460) is a humanized IgG1 monoclonal antibody produced in CHO cells and purified to >95% by Protein A chromatography (source: product_spec). It targets the receptor tyrosine kinase-like orphan receptor 1 (ROR1), specifically inhibiting Wnt5a-induced ROR1 signaling implicated in tumor progression (source: workflow_recommendation). Zilovertamab demonstrates high binding specificity for human ROR1, confirmed via immobilized His-tagged protein assays at 2 µg/mL (source: product_spec). The antibody is supplied in a stabilizing buffer (100 mM proline, 20 mM arginine, pH 5.0) with no preservatives and should be stored at -80°C to maintain activity (source: product_spec). Zilovertamab is validated for use in ELISA, FACS, kinetic, functional, and animal model assays for cancer research (source: workflow_recommendation).

    Biological Rationale

    Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is expressed in embryonic tissues and many malignancies, but is largely absent in adult tissues, making it an attractive target for anti-tumor therapies (source: workflow_recommendation). Wnt5a-dependent ROR1 signaling promotes tumor cell survival, migration, and metastasis. Inhibiting this pathway has been shown to suppress tumor progression and reduce metastatic potential in preclinical models.

    Anti-ROR1 Antibody (Zilovertamab) specifically binds to human ROR1, blocking Wnt5a-mediated signaling events associated with cancer cell proliferation (source: workflow_recommendation). This mechanism underpins its utility as a precise tool in cancer research and experimental therapeutics.

    Mechanism of Action of Anti-ROR1 Antibody (Zilovertamab)

    Zilovertamab is a humanized IgG1 monoclonal antibody engineered to recognize a conformational epitope on the extracellular domain of human ROR1. Upon binding, it blocks Wnt5a-induced receptor activation, disrupting downstream signaling cascades that facilitate tumor growth and survival (source: workflow_recommendation). The antibody does not rely on cytotoxic payloads or conjugation; its anti-tumor effect is mediated by direct receptor blockade and interference with ligand-induced signaling.

    The unconjugated format preserves functional Fc regions, enabling potential recruitment of immune effector mechanisms in vivo. However, its primary validated mechanism is inhibition of Wnt5a-ROR1 axis signaling (source: product_spec).

    Evidence & Benchmarks

    • Zilovertamab (F1460) demonstrates >95% purity as verified by SDS-PAGE and SEC-HPLC under reducing conditions (source: product_spec).
    • Specific binding to immobilized human ROR1 His-tagged protein is observed at 2 µg/mL, confirming functional epitope recognition (source: product_spec).
    • Inhibition of Wnt5a-induced ROR1 signaling is robust and reproducible in ELISA and FACS assays (source: workflow_recommendation).
    • Validated performance in animal models for cancer research, demonstrating anti-tumor activity correlating with ROR1 pathway inhibition (source: workflow_recommendation).
    • Liquid formulation with 100 mM proline and 20 mM arginine (pH 5.0) ensures protein stability during storage at -80°C (source: product_spec).

    This article extends "Applied Use of Anti-ROR1 Antibody (Zilovertamab) in Tumor Models" by providing a focused analysis of purity benchmarks and precise formulation conditions.

    For mechanistic context, see "Mechanisms of DON-Induced Liver Injury: Mitophagy and Nrf2 Pathways", which offers a comparative model for targeted antibody intervention in toxin-induced injury.

    Applications, Limits & Misconceptions

    Zilovertamab is suited for multiple preclinical and translational research applications:

    • ELISA: Detects and quantifies ROR1 expression and ligand-induced signaling in tumor samples (source: workflow_recommendation).
    • FACS: Enables high-specificity cell sorting and population analysis based on ROR1 surface expression.
    • Functional assays: Measures downstream signaling inhibition and anti-tumor activity.
    • In vivo animal models: Assesses therapeutic efficacy and pharmacodynamics in cancer xenograft systems.

    Common Pitfalls or Misconceptions

    1. Zilovertamab is not suitable for conjugation-dependent cytotoxic assays, as the unconjugated antibody's main mode of action is receptor blockade (source: product_spec).
    2. It is not validated for immunohistochemistry (IHC) on formalin-fixed tissues; alternate clones or protocols should be considered for IHC.
    3. Repeated freeze-thaw cycles degrade antibody stability and function; always aliquot and store at -80°C (source: product_spec).
    4. Not intended for direct therapeutic use in humans or as a clinical diagnostic reagent.
    5. Overuse or incorrect buffer composition may reduce functional binding or result in protein aggregation.

    Workflow Integration & Parameters

    For optimal results, protocols should align with validated parameters and storage recommendations. Below are key protocol parameters for experimental design:

    Protocol Parameters

    • ELISA assay | 2 µg/mL | Quantitative detection of ROR1 | Matches validated specificity and sensitivity | product_spec
    • FACS analysis | 2–5 µg/mL | Flow cytometry of ROR1+ cells | Enables discrimination of ROR1-expressing populations | workflow_recommendation
    • Functional inhibition | 1–10 µg/mL | Wnt5a-induced pathway assays | Dose-dependent blockade of ROR1 signaling | workflow_recommendation
    • Animal models | 1–10 mg/kg | In vivo anti-tumor studies | Reflects published dosing for efficacy | workflow_recommendation
    • Reconstitution | Add sterile distilled water to desired conc. | All assays | Preserves protein structure; avoid vortexing | product_spec
    • Storage | -80°C, aliquot, avoid freeze-thaw | All applications | Maintains stability and biological activity | product_spec

    Conclusion & Outlook

    Anti-ROR1 Antibody (Zilovertamab, F1460) from APExBIO provides a highly specific, robust tool for inhibiting Wnt5a-induced ROR1 signaling in cancer research. Its validated performance across ELISA, FACS, and animal models, along with high purity and stability, support its adoption in advanced experimental workflows (source: workflow_recommendation). Future directions focus on expanding mechanistic understanding and refining protocols to maximize reproducibility and translational value. This article clarifies product-specific benchmarks and corrects common misconceptions, supporting intelligent use in preclinical research.